Format

Send to

Choose Destination
ACS Chem Biol. 2016 Feb 19;11(2):375-80. doi: 10.1021/acschembio.5b00615. Epub 2015 Dec 7.

Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma.

Author information

1
Department of Chemistry, The Scripps Research Institute, Scripps Florida , 130 Scripps Way #3A1, Jupiter, Florida 33458, United States.

Abstract

Development of precision therapeutics is of immense interest, particularly as applied to the treatment of cancer. By analyzing the preferred cellular RNA targets of small molecules, we discovered that 5"-azido neomycin B binds the Drosha processing site in the microRNA (miR)-525 precursor. MiR-525 confers invasive properties to hepatocellular carcinoma (HCC) cells. Although HCC is one of the most common cancers, treatment options are limited, making the disease often fatal. Herein, we find that addition of 5"-azido neomycin B and its FDA-approved precursor, neomycin B, to an HCC cell line selectively inhibits production of the mature miRNA, boosts a downstream protein, and inhibits invasion. Interestingly, neomycin B is a second-line agent for hepatic encephalopathy (HE) and bacterial infections due to cirrhosis. Our results provocatively suggest that neomycin B, or second-generation derivatives, may be dual functioning molecules to treat both HE and HCC. Collectively, these studies show that rational design approaches can be tailored to disease-associated RNAs to afford potential lead therapeutics.

PMID:
26551630
PMCID:
PMC4856042
DOI:
10.1021/acschembio.5b00615
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center